###begin article-title 0
Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
Differences in MYCN/c-MYC target gene expression are associated with distinct neuroblastoma subtypes and clinical outcome.
###end p 2
###begin title 3
Background
###end title 3
###begin p 4
###xml 10 15 10 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 163 168 163 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 205 210 205 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
Amplified MYCN oncogene resulting in deregulated MYCN transcriptional activity is observed in 20% of neuroblastomas and identifies a highly aggressive subtype. In MYCN single-copy neuroblastomas, elevated MYCN mRNA and protein levels are paradoxically associated with a more favorable clinical phenotype, including disseminated tumors that subsequently regress spontaneously (stage 4s-non-amplified). In this study, we asked whether distinct transcriptional MYCN or c-MYC activities are associated with specific neuroblastoma phenotypes.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 206 211 206 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 217 220 217 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 458 463 458 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 928 932 928 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 831 838 <span type="species:ncbi:9606">patient</span>
We defined a core set of direct MYCN/c-MYC target genes by applying gene expression profiling and chromatin immunoprecipitation (ChIP, ChIP-chip) in neuroblastoma cells that allow conditional regulation of MYCN and c-MYC. Their transcript levels were analyzed in 251 primary neuroblastomas. Compared to localized-non-amplified neuroblastomas, MYCN/c-MYC target gene expression gradually increases from stage 4s-non-amplified through stage 4-non-amplified to MYCN amplified tumors. This was associated with MYCN activation in stage 4s-non-amplified and predominantly c-MYC activation in stage 4-non-amplified tumors. A defined set of MYCN/c-MYC target genes was induced in stage 4-non-amplified but not in stage 4s-non-amplified neuroblastomas. In line with this, high expression of a subset of MYCN/c-MYC target genes identifies a patient subtype with poor overall survival independent of the established risk markers amplified MYCN, disease stage, and age at diagnosis.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
High MYCN/c-MYC target gene expression is a hallmark of malignant neuroblastoma progression, which is predominantly driven by c-MYC in stage 4-non-amplified tumors. In contrast, moderate MYCN function gain in stage 4s-non-amplified tumors induces only a restricted set of target genes that is still compatible with spontaneous regression.
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 330 335 330 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 426 427 426 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 428 429 428 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 442 447 442 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 498 499 498 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 542 547 542 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 619 624 619 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 652 656 652 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">myc </italic>
###xml 811 812 811 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 813 814 813 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 409 416 <span type="species:ncbi:9606">patient</span>
###xml 681 686 <span type="species:ncbi:10090">mouse</span>
Neuroblastoma is the most common extracranial malignant solid tumor in early childhood. Clinical courses are highly variable, ranging from spontaneous regression to therapy-resistant progression. Clinical and biological features, such as age at diagnosis, disease stage, numerical (ploidy) and structural chromosomal alterations (MYCN gene amplification; 1p, 3p, 11q deletions; 17q gain), are associated with patient outcome [1,2]. Amplified MYCN oncogene identifies a subtype with poor prognosis [3] and is consistently associated with high MYCN mRNA and protein levels. There is strong experimental evidence (ectopic MYCN expression in cell lines, N-myc transgenic neuroblastoma mouse model) that increased MYCN activity is involved in tumor initiation and progression of at least a subset of neuroblastomas [4,5].
###end p 10
###begin p 11
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 31 34 31 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 45 49 45 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCL</italic>
###xml 233 234 233 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 490 491 490 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 646 650 646 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p15 </italic>
###xml 654 657 654 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p21</italic>
###xml 912 913 912 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 914 915 914 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1122 1123 1122 1123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
The MYC gene family members, c-MYC, MYCN and MYCL, are involved in the biology of many cancer types. They encode basic helix-loop-helix leucine zipper proteins that are found as heterodimers with their obligate partner protein, MAX [6]. The MYC-MAX heterodimer binds to DNA consensus core binding sites, 5'-CACGTG-3' or variants thereof (E-boxes), which preferentially leads to transcriptional activation of target genes. Repression of target genes by MYC proteins has also been described [7]. This seems to be independent of the binding of MYC proteins to E-boxes, but involves a cofactor, Miz-1, that tethers MYC-MAX to gene promoters, such as p15 and p21. Enhanced activity of MYC transcription factors contributes to almost every aspect of tumor formation: unrestricted cell proliferation, inhibition of differentiation, cell growth, angiogenesis, reduced cell adhesion, metastasis, and genomic instability [6,8]. In contrast, MYC transcription factors, including MYCN, also sensitize cells for apoptosis, a function that should inhibit tumor formation and that could also be involved in spontaneous tumor regression [9].
###end p 11
###begin p 12
###xml 420 425 420 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 505 507 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 755 757 755 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 758 760 758 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 778 783 778 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 930 932 930 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 933 935 933 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 983 988 983 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1059 1064 1059 1064 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1119 1121 1119 1121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1152 1154 1152 1154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1243 1248 1243 1248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1443 1448 1443 1448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1653 1658 1653 1658 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1744 1746 1744 1746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1747 1749 1747 1749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1890 1895 1890 1895 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1901 1905 1901 1905 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
Spontaneous tumor regression does occur in neuroblastoma, at a higher frequency than in any other cancer type. This process resembles the physiological concurrence of massive cellular suicide (apoptosis) and differentiation of a few neurons along the sympathoadrenal cell lineage in the normal development of the sympathetic nervous system. Spontaneous regression is most frequently observed in a subset of disseminated MYCN single-copy neuroblastomas (non-amplified (NA)), termed stage 4s (stage 4s-NA) [10]. However, population-based screening studies for neuroblastomas in Japan, Quebec and Germany suggest that spontaneous regression also occurs in other neuroblastoma subtypes, predominantly localized (stages 1, 2, 3) neuroblastomas (localized-NA) [11-13]. Paradoxically, MYCN mRNA and protein levels are higher in favorable localized-NA and, particularly, in stage 4s-NA tumors than in stage 4-NA tumors with poor outcome [14-16], but they do not reach the levels observed in MYCN amplified tumors. In line with this, neuroblastoma cells with elevated MYCN expression retain their capacity to undergo apoptosis [17] or neuronal differentiation [18]. Thus, it has been speculated that MYCN does not only mediate malignant progression in MYCN amplified tumors, but is also either involved or at least compatible with spontaneous regression in favorable neuroblastomas. In contrast, a functional role of MYCN in stage 4-NA tumors with low MYCN levels is questionable. Here, other transcription factors or pathways within or outside the MYC family of transcription factors could be more relevant. Neuroblastoma-derived cell lines that lack amplified MYCN generally express c-MYC rather than MYCN, often at higher levels than normal tissues [19,20]. However, transcriptional activity of MYCN or c-MYC as reflected by the transcript levels of direct MYCN/c-MYC target genes in relation to MYCN and c-MYC levels has not yet been defined in neuroblastoma subtypes.
###end p 12
###begin p 13
###xml 164 169 164 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 174 177 174 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 547 552 547 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 558 562 558 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 763 767 763 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
Here, we defined a core set of MYCN and c-MYC target genes by using oligonucleotide microarrays and a neuroblastoma cell line that allows conditional expression of MYCN or c-MYC. Direct regulation of these target genes by MYCN/c-MYC was assessed by analyzing the binding of MYCN and c-MYC protein to target gene promoters using PCR- and array-based chromatin immunoprecipitation (ChIP and ChIP-chip, respectively) in different neuroblastoma cell lines. We further investigated the expression of these direct MYCN/c-MYC target genes in relation to MYCN and c-MYC expression in different clinical neuroblastoma subtypes. In addition, the association of MYCN/c-MYC target gene expression with overall survival independent of the well-established markers - amplified MYCN, disease stage and age at diagnosis - was demonstrated.
###end p 13
###begin title 14
Results
###end title 14
###begin title 15
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 34 38 34 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
Inverse correlation of MYCN and c-MYC expression in neuroblastoma subtypes
###end title 15
###begin p 16
###xml 2 6 2 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 64 65 64 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 115 119 115 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 136 138 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 247 252 247 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 311 313 311 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 371 373 371 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 382 384 382 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 428 433 428 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 503 508 503 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 534 538 534 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 542 547 542 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 664 668 664 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 749 753 749 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 892 897 892 897 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 903 907 903 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 1015 1020 1015 1020 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1047 1050 1047 1050 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 1108 1112 1108 1112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 1137 1142 1137 1142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1150 1151 1150 1151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1153 1155 1153 1155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1169 1172 1169 1172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 1174 1176 1174 1176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1187 1191 1187 1191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 209 217 <span type="species:ncbi:9606">patients</span>
c-MYC mRNA levels are very low in MYCN amplified tumors (Figure 1), which is due to high MYCN protein repressing c-MYC mRNA expression [20]. Previous quantitative PCR analyses in a cohort of 117 neuroblastoma patients revealed that mRNA levels of MYCN are significantly lower in stage 4-NA than in stage 4s-NA (p = 0.008) and localized-NA neuroblastomas (stages 1, 2, 3; p = 0.03) [14]. To test whether this lower expression of MYCN in stage 4-NA tumors is due to elevated c-MYC activity that represses MYCN expression, we analyzed c-MYC and MYCN mRNA levels in a cohort of 251 primary neuroblastoma tumors using a customized 11K oligonucleotide microarray (other MYC gene family members were not differently expressed (data not shown)). Although c-MYC mRNA levels were not significantly higher in stage 4-NA (n = 52) than in localized-NA tumors (n = 138), we found an inverse correlation of MYCN and c-MYC expression between stage 4s-NA (n = 30) and stage 4-NA tumors. Stage 4-NA tumors showed lower expression of MYCN and higher expression of c-MYC, whereas stage 4s-NA tumors showed lower expression of c-MYC and higher expression of MYCN (Figure 1; p = 0.008 for c-MYC, p = 0.07 for MYCN).
###end p 16
###begin p 17
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 34 38 34 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 115 120 115 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 126 130 126 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 145 149 145 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2</italic>
###xml 151 155 151 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKC1</italic>
###xml 161 165 161 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTMA</italic>
###xml 657 662 657 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 757 762 757 762 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 950 952 950 952 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
Inverse correlation of MYCN and c-MYC mRNA levels in neuroblastoma subtypes. Relative mRNA expression is shown for MYCN and c-MYC as well as for MDM2, DKC1, and PTMA, three direct targets of MYCN/c-MYC. Data are represented as box plots: horizontal boundaries of boxes represent the 25th and 75th percentile. The 50th percentile (median) is denoted by a horizontal line in the box and whiskers above and below extend to the most extreme data point, which is no more than 1.5 times the interquartile range from the box. A set of 251 primary neuroblastoma tumors was analyzed consisting of 138 localized-NA (stage 1/2/3), 30 stage 4s-NA, 52 stage 4-NA and 31 MYCN amplified (AMP) neuroblastoma tumors. Gene expression levels from stage 4s-NA, stage 4-NA, and MYCN amplified tumors were compared pair-wise with those of localized-NA tumors as reference. Differential gene expression was assessed for each gene by using the Mann-Whitney test (cut-off of p < 0.05).
###end p 17
###begin p 18
###xml 239 244 239 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 250 255 250 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKC1 </italic>
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 265 270 265 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTMA </italic>
###xml 271 273 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 380 385 380 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 410 411 410 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 413 415 413 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 459 464 459 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 503 505 503 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 531 533 531 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 594 599 594 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 623 628 623 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 683 688 683 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 718 723 718 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKC1 </italic>
###xml 727 732 727 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTMA </italic>
###xml 769 771 769 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 783 787 783 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKC1</italic>
###xml 789 791 789 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 802 806 802 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTMA</italic>
###xml 828 830 828 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 841 845 841 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKC1</italic>
###xml 847 849 847 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 861 865 861 865 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTMA</italic>
###xml 1067 1072 1067 1072 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKC1 </italic>
###xml 1116 1121 1116 1121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTMA </italic>
Because increased activity of MYCN in stage 4s-NA or c-MYC in stage 4-NA tumors should both result in high expression of shared target genes compared to localized-NA neuroblastomas, we analyzed known direct MYCN/c-MYC target genes, namely MDM2 [21], DKC1 [22], and PTMA [23], in neuroblastoma subtypes. As expected, the highest expression of all three transcripts was observed in MYCN amplified tumors (Figure 1; p < 0.001 for all three transcripts, n = 31). MDM2 mRNA levels were higher in stage 4-NA (p = 0.005) and stage 4s-NA (p = 0.03) than in localized-NA tumors (the expression range of MDM2 is large because of two MYCN amplified tumors with non-syntenic co-amplification of MDM2 (data not shown)). Similarly, DKC1 and PTMA expression was higher in stage 4-NA (p < 0.001 for DKC1, p = 0.02 for PTMA) and in stage 4s-NA (p = 0.03 for DKC1, p = 0.007 for PTMA) than in localized-NA tumors. These results suggest an increased MYCN/c-MYC activity also in stage 4s-NA (MYCN) and in stage 4-NA (predominantly c-MYC) compared to localized-NA tumors. However, higher DKC1 mRNA levels in stage 4-NA tumors and higher PTMA mRNA levels in stage 4s-NA tumors also suggest differential regulation of MYCN/c-MYC target genes in these subtypes. To further analyze MYCN/c-MYC activity as well as differential regulation of MYCN/c-MYC target genes in neuroblastoma subtypes, we thought to define a comprehensive set of target genes directly regulated by MYCN and/or c-MYC in neuroblastoma cells.
###end p 18
###begin title 19
###xml 27 31 27 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 59 64 59 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 82 87 82 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 82 87 82 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN </italic></sup>
Repression of endogenous c-MYC by targeted expression of a MYCN transgene in SH-EPMYCN cells defines c-MYC- and MYCN-regulated genes
###end title 19
###begin p 20
###xml 104 108 104 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 104 108 104 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN</italic></sup>
###xml 158 163 158 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 206 211 206 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 206 211 206 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN </italic></sup>
###xml 293 295 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 531 533 531 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 599 604 599 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTMA </italic>
###xml 608 612 608 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKC1</italic>
###xml 777 782 777 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 786 791 786 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCM7 </italic>
To identify MYCN/c-MYC-regulated genes in neuroblastoma cells, we employed the experimental system SH-EPMYCN, which stably expresses a tetracycline-regulated MYCN transgene [23]. Exponentially growing SH-EPMYCN cells cultured with tetracycline express c-MYC but almost no MYCN protein (Figure 2a). Induction of MYCN by removing tetracycline from the medium is associated with a rapid reduction of c-MYC at the mRNA and protein levels. c-MYC reduction occurs prior to the full expression of ectopically induced MYCN protein (Figure 2a). Accordingly, mRNA levels of direct MYCN/c-MYC targets, such as PTMA and DKC1, initially decline before accumulating MYCN protein leads to the re-induction of these genes. Similar profiles were observed with direct MYCN target genes, such as MDM2 and MCM7 (Additional data file 1).
###end p 20
###begin p 21
###xml 86 90 86 90 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 149 154 149 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 172 177 172 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 172 177 172 177 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN </italic></sup>
###xml 339 344 339 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 339 344 339 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN </italic></sup>
###xml 395 400 395 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 470 473 470 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC</italic>
###xml 475 480 475 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKC1 </italic>
###xml 484 489 484 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTMA </italic>
###xml 592 596 592 596 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 874 878 874 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 874 878 874 878 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN</italic></sup>
###xml 916 920 916 920 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 965 969 965 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 2056 2060 2056 2060 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 2056 2060 2056 2060 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN</italic></sup>
###xml 1219 1224 <span type="species:ncbi:9606">human</span>
###xml 1264 1269 <span type="species:ncbi:9606">human</span>
Identification and validation of MYCN/c-MYC target genes in neuroblastoma cell lines. (a) Repression of endogenous c-MYC by targeted expression of a MYCN transgene in SH-EPMYCN cells defines MYCN/c-MYC-regulated genes. MYCN and c-MYC protein levels were monitored in a time series after removing tetracycline in exponentially growing SH-EPMYCN cells that stably express a tetracycline-regulated MYCN transgene. Mean and standard deviation of the relative mRNA levels of MYC, DKC1 and PTMA are given from two time series experiments as measured by a customized neuroblastoma oligo microarray. (b) Hierarchical clustering of MYCN- and c-MYC binding to 140 target gene promoters as measured by ChIP-chip in 6 neuroblastoma cell lines. ChIP-chip results of 140 MYCN/c-MYC target genes from 5 neuroblastoma cell lines that preferentially express either high levels of MYCN (SH-EPMYCN, IMR5/75 (approximately 75 copies of MYCN) and Kelly (approximately 100-120 copies of MYCN)) or c-MYC (SJ-NB12 and SY5Y). Additionally, as an intermediate type, parental SH-EP cells were analyzed. SH-EP cells preferentially express c-MYC, but also low levels of MYCN. ChIP-chip experiments were performed with a monoclonal antibody against human MYCN and a polyclonal antibody against human c-MYC for each neuroblastoma cell line. A cut-off for positive binding was set for both transcription factors to >4-fold enrichment for one and >2-fold enrichment of at least one of the two neighboring probes. MYCN/c-MYC-binding is color-coded as follows: blue, c-MYC binding; red, MYCN/c-MYC binding; dark red, MYCN binding; light yellow, lack of MYCN/c-MYC binding. Hierarchical clustering was used to group neuroblastoma cell lines according to their MYCN/c-MYC-binding pattern. Differentiation between MYCN and c-MYC-binding was mainly achieved through the monoclonal MYCN antibody. The polyclonal antibody against c-MYC also gave positive binding signals for a large set of analyzed target gene promoters in neuroblastoma cell lines with high MYCN that lack c-MYC expression (SH-EPMYCN, IMR5/75 and Kelly).
###end p 21
###begin p 22
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 13 18 13 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN </italic></sup>
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 307 309 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 345 350 345 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 345 350 345 350 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN </italic></sup>
###xml 404 409 404 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 835 837 835 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1071 1073 1071 1073 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1209 1214 1209 1214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1209 1214 1209 1214 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN </italic></sup>
###xml 1409 1414 1409 1414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1409 1414 1409 1414 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN </italic></sup>
###xml 1639 1641 1639 1641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 1806 1811 1806 1811 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1806 1811 1806 1811 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN </italic></sup>
###xml 1905 1910 1905 1910 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1905 1910 1905 1910 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN </italic></sup>
###xml 2365 2367 2365 2367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 2430 2435 2430 2435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 2430 2435 2430 2435 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN </italic></sup>
###xml 2682 2687 2682 2687 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 2682 2687 2682 2687 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN </italic></sup>
We used SH-EPMYCN cells for a global search of MYCN and c-MYC target genes in neuroblastoma cells using a customized neuroblastoma oligonucleotide microarray (11K, Agilent) that was enriched with probes for genes differentially expressed in neuroblastoma subtypes and for direct MYCN/c-MYC target genes [14,24]. Gene expression profiles of SH-EPMYCN cells at 2, 4, 8, 12, 24, and 48 hours after targeted MYCN expression were generated. Self-organizing maps (SOMs) were used to capture the predominant pattern of gene expression. This analysis yielded 504 clusters (best matching units (BMUs)) consisting, on average, of 20 clones per cluster (Additional data file 1). We searched for clusters with characteristic gene expression profiles of direct MYCN/c-MYC target genes. In addition, known c-MYC target genes from a public database [25] and known MYCN target genes from a literature search were mapped to the 504 clusters (Additional data file 2). A significant enrichment of known MYCN/c-MYC targets was found in 6 clusters (clusters 140, 168, 195, 280, 308, and 336; p < 0.05, adjusted for multiple testing), consisting of 167 genes. The genes in these six clusters were induced by MYCN and c-MYC in SH-EPMYCN cells. Based on their average gene expression profiles, we grouped the clusters into two subgroups, I and II. Subgroup I genes (clusters 140, 168, and 195) were expressed at equal levels in SH-EPMYCN cells expressing endogenous c-MYC (2 hours) and in those fully expressing ectopic MYCN (24 and 48 hours), despite the fact that the maximum protein level of MYCN was significantly higher than that of endogenous c-MYC (Figure 2a; Additional data file 1). This indicates that subgroup I genes are regulated by MYCN, and also suggests that they are less responsive to MYCN than to c-MYC in SH-EPMYCN cells. The mRNA levels of subgroup II genes (clusters 280, 308, and 336) were highest in SH-EPMYCN cells fully expressing ectopic MYCN and followed the combined absolute c-MYC and MYCN protein levels during the time course experiment. We also found clusters with MYCN and c-MYC repressed genes (for example, subgroup III; Additional data file 1). However, enrichment of known MYCN/c-MYC repressed genes from the literature/database in defined clusters was not found using our statistical cut-off (after adjustment for multiple testing, no cluster showed p < 0.05). This was at least partly due to the fact that in SH-EPMYCN cells, some genes were repressed by MYCN but not by c-MYC (subgroup IV). In addition, c-MYC repressed genes from different experimental systems compiled in the c-MYC target gene database were not necessarily repressed by MYCN and/or c-MYC in SH-EPMYCN cells.
###end p 22
###begin p 23
###xml 112 117 112 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 112 117 112 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN </italic></sup>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
Therefore, we focused on genes for further validation that were induced by both MYCN and c-MYC proteins in SH-EPMYCN cells and grouped into subgroup I and II. We extracted all available promoters from the genes represented on the array and scanned for canonical E-boxes (CACGTG) and for the 12 bp MYCN position-weight matrix [26] within -2 kb and +2 kb of the transcriptional start site. We ranked all 504 clusters according to the relative number of putative MYCN/c-MYC binding sites in each cluster. All clusters from subgroups I and II were among the 15 top-ranked clusters with enrichment of predicted MYCN/c-MYC binding sites (data not shown).
###end p 23
###begin p 24
###xml 412 416 412 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 412 416 412 416 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN</italic></sup>
###xml 454 458 454 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 504 508 504 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 679 681 679 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 682 684 682 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1784 1786 1784 1786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 2281 2285 2281 2285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 2281 2285 2281 2285 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN</italic></sup>
###xml 759 764 <span type="species:ncbi:9606">human</span>
###xml 804 809 <span type="species:ncbi:9606">human</span>
To further validate target gene regulation by MYCN/c-MYC in neuroblastoma cells, we performed ChIP-chip using a 244K oligonucleotide promoter microarray (Agilent). We analyzed the binding of MYCN and c-MYC to the promoters of the 147 subgroup I and II genes that were represented on the 244K promoter microarray. We used five neuroblastoma cell lines that either preferentially express high levels of MYCN (SH-EPMYCN, IMR5/75 (approximately 75 copies of MYCN), and Kelly (approximately 100-120 copies of MYCN)) or c-MYC (SJ-NB12 and SY5Y). Additionally, as an intermediate type, parental SH-EP cells were analyzed, which preferentially express c-MYC, but also MYCN at low level [20,23]. ChIP-chip experiments were performed with a monoclonal antibody against human MYCN and a polyclonal antibody against human c-MYC for each of the neuroblastoma cell lines. A cut-off for positive binding was defined as >4-fold enrichment for one probe together with >2-fold enrichment for at least one of the two neighboring probes compared to input control. In addition, we manually inspected each of the MYCN and c-MYC-binding profiles from the 147 genes. Seven genes were excluded from the analysis because the probe sets for the genes mapped within the genes but outside the target gene promoter regions (all profiles for Kelly and SJ-NB12 cell lines are given in Additional data files 3 and 4, respectively; MYCN- and c-MYC-binding results are given in Additional data files 5-7). We also performed PCR-based ChIP for selected candidate genes (n = 13; Additional data file 8), which all showed analogous results to ChIP-chip (data not shown). Almost all 140 target gene promoters showed binding of MYCN and/or c-MYC in the six analyzed neuroblastoma cell lines as measured by ChIP-chip (Figure 2b). Intriguingly, hierarchical clustering of neuroblastoma cell lines according to the MYCN/c-MYC-binding pattern clearly separated MYCN- and c-MYC-expressing neuroblastoma cell lines. Differentiation between MYCN and c-MYC binding was mainly achieved through the monoclonal anti-MYCN antibody. The polyclonal antibody against c-MYC also gave positive binding signals for a large set of target gene promoters in neuroblastoma cell lines with high MYCN that lack detectable c-MYC expression (SH-EPMYCN, IMR5/75 and Kelly). This was most likely due to unspecific binding of the polyclonal c-MYC antibody to MYCN in these cells. Nevertheless, the lack of binding of MYCN to a large set of target gene promoters in the c-MYC-expressing cells, SJ-NB12 and SY5Y, and the positive binding of c-MYC to almost all of these target gene promoters in these cells allowed the distinction between MYCN and c-MYC. Taken together, these results indicate that the genes from subgroups I and II represent a core set of target genes directly regulated by either MYCN or c-MYC in neuroblastoma cells dependent on which MYC protein is expressed.
###end p 24
###begin title 25
###xml 93 98 93 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
Gradual increase of MYCN/c-MYC target gene expression from stage 4s-NA through stage 4-NA to MYCN amplified tumors
###end title 25
###begin p 26
###xml 231 236 231 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 314 319 314 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 573 575 573 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 597 599 597 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 612 617 612 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 635 637 635 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 789 794 789 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 986 988 986 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1059 1064 1059 1064 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1128 1133 1128 1133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1206 1211 1206 1211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1256 1261 1256 1261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1311 1312 1311 1312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 1403 1407 1403 1407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCT4</italic>
###xml 1409 1412 1409 1412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FBL</italic>
###xml 1414 1418 1414 1418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2</italic>
###xml 1420 1423 1420 1423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NCL</italic>
###xml 1425 1429 1425 1429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NPM1</italic>
###xml 1431 1435 1431 1435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTMA</italic>
###xml 1441 1445 1441 1445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
###xml 1508 1509 1508 1509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1712 1713 1712 1713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1863 1867 1863 1867 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHCY</italic>
###xml 1869 1875 1869 1875 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUVBL1</italic>
###xml 1877 1880 1877 1880 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PHB</italic>
###xml 1882 1886 1882 1886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDK4</italic>
###xml 1892 1897 1892 1897 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL3</italic>
###xml 1904 1909 1904 1909 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1965 1970 1965 1970 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 2262 2271 2262 2271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 2320 2325 2320 2325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 2386 2391 2386 2391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 2423 2432 2423 2432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 2494 2499 2494 2499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 2560 2565 2560 2565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 2571 2575 2571 2575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
To determine transcriptional activity of MYCN/c-MYC proteins in primary neuroblastomas (n = 251), we analyzed differential expression of subgroup I and II genes in neuroblastoma subtypes using the Global test as proposed by Goeman et al. [27]. Almost all these genes (154 of 167; 92%) showed highest expression in MYCN amplified tumors, suggesting that regulation of these genes by MYCN is similar in neuroblastoma cell lines and tumors. Compared to localized-NA tumors (stages 1, 2, 3), expression of subgroup I and II genes was significantly associated with stage 4s-NA (p = 0.002), stage 4-NA (p < 0.001) and MYCN amplified tumors (p < 0.001). Global test results further indicated that an increasing number of MYCN/c-MYC target genes was induced from stage 4s-NA through stage 4-NA to MYCN amplified tumors (Additional data files 9-11). To further illustrate this, we grouped each of the 154 genes into one of four classes based on pair-wise comparisons (Mann-Whitney test, cut-off p < 0.05). These were, compared to localized-NA tumors: overexpressed in MYCN amplified and in stage 4s-NA tumors (class 1); overexpressed in MYCN amplified, stage 4-NA and stage 4s-NA tumors (class 2); overexpressed in MYCN amplified tumors (class 3); overexpressed in MYCN amplified and stage 4-NA tumors (class 4) (Figure 3). Compared to localized-NA tumors, 25 (16%) of the 154 MYCN/c-MYC target genes, including CCT4, FBL, MDM2, NCL, NPM1, PTMA, and TP53, were expressed at higher levels in stage 4s-NA tumors (Table 1). Eighty-eight (57%) of the 154 MYCN/c-MYC target genes, including 21 of those overexpressed also in stage 4s-NA tumors, were expressed at higher levels in stage 4-NA than in localized-NA tumors (Table 1, class 2; Additional data file 5). Accordingly, stage 4-NA tumors shared overexpression of 68 of 154 direct MYCN/c-MYC target genes (44%), including AHCY, RUVBL1, PHB, CDK4, and MRPL3, with MYCN amplified tumors. Together, this indicates that besides MYCN amplified tumors, stage 4-NA tumors, and to a lesser extent stage 4s-NA tumors, also show higher MYCN/c-MYC activity compared to localized-NA tumors. In line with this, we also found lower mRNA levels of an increasing number of MYCN/c-MYC repressed genes from stage 4s-NA (10 out of 68 (15%) in vitro validated repressed genes that are also lower in MYCN amplified tumors) through stage 4-NA (34 out of 68 (50%)) to MYCN amplified tumors (68 out of 102 in vitro validated repressed genes had the lowest expression levels in MYCN amplified tumors (67%)). Based on the relative expression of MYCN and c-MYC in neuroblastoma subtypes, we propose that elevated MYCN activity in stage 4s-NA tumors induces only a restricted set of MYCN/c-MYC target genes, whereas elevated c-MYC activity in stage 4-NA tumors induces a larger set of MYCN/c-MYC target genes.
###end p 26
###begin p 27
MYCN/c-MYC target genes overexpressed in stage 4s-NA compared to localized-NA tumors (classes 1 and 2)
###end p 27
###begin p 28
###xml 32 37 32 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 32 37 32 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN </italic></sup>
###xml 49 54 49 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 65 71 65 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8224;</sup>
###xml 105 107 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 152 165 147 148 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8225;</sup>
*Fold change expression in SH-EPMYCN cells after MYCN induction. daggerc-MYC target gene database entry [25]: Up, upregulated; ChIP, validated by ChIP. double daggerValidation of MYCN/c-MYC binding using ChIP in this study (Additional data files 5-7). BMU, best matching unit; ND, not determined.
###end p 28
###begin p 29
###xml 137 142 137 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 299 301 299 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 529 534 529 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 580 585 580 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCT4 </italic>
###xml 589 592 589 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NCL</italic>
###xml 612 617 612 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 672 677 672 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 681 684 681 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FBL</italic>
###xml 704 709 704 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 736 743 736 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MTHFD2 </italic>
###xml 747 753 747 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EEF1E1</italic>
###xml 777 782 777 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 824 829 824 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHCY </italic>
###xml 833 838 833 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL3</italic>
Expression of MYCN/c-MYC target genes in neuroblastoma subtypes. Differential expression was analyzed for each of the genes (n = 154) in MYCN amplified (AMP), stage 4s-NA and stage 4-NA tumors using localized-NA (stage 1/2/3) tumors as reference in pair-wise comparisons (Mann-Whitney test, cut-off p < 0.05, black). We grouped each of these 154 genes into one of four classes based on their relative expression in clinically relevant neuroblastoma subtypes. These classes were, compared to localized-NA tumors: overexpressed in MYCN amplified and in stage 4s-NA tumors (class 1; CCT4 and NCL); overexpressed in MYCN amplified, stage 4-NA and stage 4s-NA tumors (class 2; TP53 and FBL); overexpressed in MYCN amplified tumors (class 3; MTHFD2 and EEF1E1); and overexpressed in MYCN amplified and stage 4-NA tumors (class 4; AHCY and MRPL3).
###end p 29
###begin title 30
###xml 110 115 110 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
High expression of MYCN/c-MYC target genes is a robust marker of poor overall survival independent of genomic MYCN status, age at diagnosis and disease stage
###end title 30
###begin p 31
###xml 504 505 504 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 636 637 636 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 919 923 919 923 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 1005 1006 1003 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 1105 1107 1103 1105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1323 1325 1321 1323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1475 1479 1473 1477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 1713 1717 1709 1713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 1713 1717 1709 1713 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN</italic></sup>
###xml 1836 1837 1832 1833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 1847 1848 1843 1844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 2017 2021 2013 2017 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHCY</italic>
###xml 2023 2028 2019 2024 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARD1A</italic>
###xml 2030 2034 2026 2030 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDK4</italic>
###xml 2036 2041 2032 2037 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HSPD1</italic>
###xml 2043 2046 2039 2042 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PHB</italic>
###xml 2048 2054 2044 2050 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RUVBL1</italic>
###xml 2060 2065 2056 2061 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TRAP1</italic>
###xml 2387 2389 2383 2385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 2546 2550 2542 2546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 3313 3318 3307 3312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 3321 3323 3315 3317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 3383 3388 3377 3382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DDX21</italic>
###xml 3390 3397 3384 3391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SCL25A3</italic>
###xml 3399 3406 3393 3400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EIFA4A2</italic>
###xml 3408 3412 3402 3406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NME1</italic>
###xml 3414 3418 3408 3412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NME2</italic>
###xml 3420 3423 3414 3417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TKT</italic>
###xml 3425 3429 3419 3423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LDHA</italic>
###xml 3431 3435 3425 3429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LDHB</italic>
###xml 3437 3442 3431 3436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HSPD1</italic>
###xml 3444 3449 3438 3443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HSPCB</italic>
###xml 3560 3565 3554 3559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 3568 3570 3562 3564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 3629 3634 3623 3628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EEF1G</italic>
###xml 3636 3640 3630 3634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHCY</italic>
###xml 3642 3646 3636 3640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
###xml 3648 3652 3642 3646 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENO1</italic>
###xml 3654 3657 3648 3651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TKT</italic>
###xml 3776 3781 3770 3775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 3784 3786 3778 3780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 3845 3850 3839 3844 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRDX4</italic>
###xml 3852 3857 3846 3851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MRPL3</italic>
###xml 3859 3864 3853 3858 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNRPE</italic>
###xml 3866 3869 3860 3863 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FBL</italic>
###xml 3871 3880 3865 3874 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LOC200916</italic>
###xml 3882 3887 3876 3881 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAICS</italic>
###xml 3889 3893 3883 3887 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AHCY</italic>
###xml 3902 3903 3896 3897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
Having shown that MYCN/c-MYC target gene activation is also associated with distinct neuroblastoma subtypes, we wanted to test whether MYCN/c-MYC activity as determined by the expression levels of their target genes is associated with overall survival and improves outcome prediction independent of known risk markers. We used the Global test to test the influence of each of the 504 experimentally defined gene clusters on overall survival directly, without the intermediary of single gene testing. The p-values for each cluster were adjusted for multiple testing and ranked according to their association with overall survival. Table 2 gives the association with overall survival of the six MYCN/c-MYC target gene clusters and the rank in relation to all other clusters. In a separate analysis, we determined the association with overall survival for each of the 504 experimental gene clusters adjusted for amplified MYCN, stage 4 versus stages 1, 2, 3, and 4s, and age at diagnosis >/=1.5 years (Table 2). These well-established risk markers highly correlated with poor outcome in univariate analyses (p < 0.001 for each of these three markers). As expected, the Global test without adjustment for co-variables indicated that all MYCN/c-MYC target gene clusters were significantly associated with poor overall survival (p < 0.001). Intriguingly, all six MYCN/c-MYC target gene clusters remained significantly associated with overall survival after adjusting for amplified MYCN, stage 4 versus stages 1, 2, 3, and 4s, and age at diagnosis >/=1.5 years. Of note, two of the MYCN/c-MYC target gene clusters (clusters 168 and 140, both from subgroup I showing a higher responsiveness to c-MYC than to MYCN in SH-EPMYCN) revealed the strongest association with overall survival of all 504 clusters after adjusting for co-variables (Table 2). Figure 4 shows the association with overall survival for each gene from cluster 168 with and without adjustment for co-variables. Most of the genes within this cluster, such as AHCY, ARD1A, CDK4, HSPD1, PHB, RUVBL1, and TRAP1, remained associated with overall survival after adjustment for co-variables. A less significant association with overall survival was observed for clusters with MYCN/c-MYC repressed genes: clusters 454, 482, 484, and 486 were associated with poor overall survival without adjustment for co-variables in the Global test (p < 0.001, adjusted for multiple testing), but they showed no significant association with poor overall survival when adjusting for the co-variables amplified MYCN, stage 4 versus stages 1, 2, 3, and 4s, and age at diagnosis >/=1.5 years. We also asked whether direct MYCN/c-MYC target genes as defined by our analyses are represented in previously published gene expression-based classifiers that distinguish low-risk from high-risk neuroblastomas independent of other risk markers. Gene lists from these studies hardly overlapped, making interpretation difficult. The overlap with our MYCN/c-MYC target gene list was defined by using the gene names as common identifiers. Indeed, different genes defined by our study as direct MYCN/c-MYC target genes were represented in the gene expression classifier gene lists: from the 44 genes overexpressed in high-risk neuroblastomas independent of other markers described by Schramm et al. [28], we identified 10 genes directly regulated by MYCN/c-MYC (DDX21, SCL25A3, EIFA4A2, NME1, NME2, TKT, LDHA, LDHB, HSPD1, HSPCB); from the 20 genes overexpressed in high-risk neuroblastomas independent of other markers described by Ohira et al. [29], we identified 5 genes directly regulated by MYCN/c-MYC (EEF1G, AHCY, TP53, ENO1, TKT); and from the 66 genes overexpressed in high-risk neuroblastomas independent of other markers described by Oberthuer et al. [24], we identified 7 genes directly regulated by MYCN/c-MYC (PRDX4, MRPL3, SNRPE, FBL, LOC200916, PAICS, AHCY; Figure 5). Together, these results show that MYCN/c-MYC activity as determined by the expression status of a subset of MYCN/c-MYC target genes is significantly associated with poor overall survival independent of other established markers and is a consistent element of gene expression-based neuroblastoma risk classification systems.
###end p 31
###begin p 32
Association of MYCN/c-MYC target gene clusters with overall survival in primary neuroblastomas (n = 251)
###end p 32
###begin p 33
###xml 158 162 158 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 225 231 223 224 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8224;</sup>
###xml 231 232 224 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 384 389 377 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 384 389 377 382 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN </italic></sup>
*Rank of all 504 clusters tested for association with overall survival (OS) using the Global test without and with adjustment for co-variables (CV; amplified MYCN, stages 1, 2, 3, 4s versus 4, age at diagnosis >/=1.5 years). daggerp-value from Global test adjusted for multiple testing. In the Cluster column, I or II gives the cluster group as defined by the SOM analysis using SH-EPMYCN cells.
###end p 33
###begin p 34
###xml 274 279 274 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
Association of cluster 168 genes with overall survival. The two gene plots illustrate the influence on overall survival of each gene from cluster 168. The gene plot gives the influence on overall survival without (left) and with (right) adjustment for the variables genomic MYCN status, age at diagnosis (>/=1.5 years), and disease stage (stages 1, 2, 3, 4s versus stage 4). The gene plot shows a bar and a reference line for each gene tested. In a survival model, the expected height is zero under the null hypothesis that the gene is not associated with the clinical outcome (= reference line). Marks in the bars indicate by how many standard deviations the bar exceeds the reference line. The bars are colored to indicate a negative (red) association of a gene's expression with overall survival. In addition, the boxplot class is given for each gene.
###end p 34
###begin p 35
###xml 394 399 394 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1139 1144 1137 1142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1139 1144 1137 1142 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN </italic></sup>
###xml 236 244 <span type="species:ncbi:9606">patients</span>
Representation of MYCN/c-MYC target genes in a gene expression-based neuroblastoma risk stratification system. Two-way hierarchical cluster analysis using 144 oligonucleotide probes from the gene expression-based classifier and the 251 patients from the entire cohort. Clinical characteristics (outcome, white = no event, gray = relapse/progression, black = death due to neuroblastoma; genomic MYCN status, white = NA, black = amplified; chromosome 1p status, white = normal, black = 1p deleted, gray = not available; chromosome 11q status, white = normal, black = 11q deleted, gray = not available; age at diagnosis, white <1.5 years, black >/=1.5 years; disease stage, white = stage 1, 2, gray = stage 3, yellow = stage 4s, black = stage 4) are added to the heatmap of gene expression. The gene expression cluster with direct MYCN/c-MYC target genes is highlighted. The Rank Classifier column gives the classifier rank found by the Prediction Analysis for Microarrays algorithm and a complete 10-times-repeated 10-fold cross validation. The Cluster column gives the results from the SOM analysis using gene expression profiles from SH-EPMYCN cells. The MYCN/c-MYC regulated column gives the fold changes after MYCN induction. The Ebox column gives the position of a canonical E-box in the promoter. The c-MYC TGDB column gives the entries in the public c-MYC target gene database. *UP, upregulated.
###end p 35
###begin title 36
Discussion
###end title 36
###begin p 37
###xml 241 246 241 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 295 300 295 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 330 335 330 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 516 521 516 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 582 584 582 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 585 587 585 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 722 727 722 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 733 737 733 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 978 980 978 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1371 1375 1371 1375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 1396 1401 1396 1401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1521 1526 1521 1526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1539 1543 1539 1543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 1657 1659 1657 1659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
In this study, we analyzed MYCN and c-MYC activity as reflected by the expression levels of a core set of direct MYCN/c-MYC targets in neuroblastoma subtypes. As expected, the highest expression levels of MYCN/c-MYC targets were observed in MYCN amplified tumors. However, we found that besides MYCN amplified tumors, subtypes of MYCN single-copy tumors, namely stage 4-NA and, to a lesser extent, stage 4s-NA, also showed increased MYCN/c-MYC target gene activation compared to localized-NA tumors. In general, low MYCN mRNA and protein levels are found in most stage 4-NA tumors [14-16], which does not explain the high mRNA levels of MYCN/c-MYC target genes in this subtype. Here, we describe an inverse correlation of MYCN and c-MYC expression levels in stage 4-NA and stage 4s-NA tumors. From experiments in neuroblastoma cell lines, it is known that MYCN and c-MYC control their expression via autoregulatory loops and via repressing each other at defined promoter sites [20]. Neuroblastoma cell lines with high expression of MYCN as a result of amplification lack c-MYC expression. Whenever MYCN and c-MYC are co-expressed in neuroblastoma cell lines, c-MYC expression predominates. Together, this suggests that increased activity of c-MYC represses MYCN in a substantial number of stage 4-NA tumors. In contrast, an inverse regulation, namely the repression of c-MYC by MYCN, is found in MYCN amplified and, to a lesser extent, in stage 4s-NA tumors. It is important to note that localized-NA tumors also express MYCN as well as c-MYC and it is likely that they are active because these tumors frequently show high tumor cell proliferation indices [14]. Nevertheless, in localized-NA tumors, we did not observe that one MYC transcription factor dominates over the other, such as in the other neuroblastoma subtypes.
###end p 37
###begin p 38
###xml 128 133 128 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 240 245 240 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 739 744 739 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTMA </italic>
###xml 1029 1034 1029 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1029 1034 1029 1034 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN </italic></sup>
###xml 1443 1445 1443 1445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1502 1504 1502 1504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1505 1507 1505 1507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1538 1542 1538 1542 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
Our findings further indicate that MYCN/c-MYC target gene activation gradually increases from stage 4s-NA through stage 4-NA to MYCN amplified tumors. High expression of a large number of MYCN/c-MYC target genes was found in stage 4-NA and MYCN amplified tumors, but not in stage 4s-NA tumors, which is probably involved in the divergent clinical outcome of these subtypes. This also suggests that MYCN in stage 4s tumors is a weaker transactivator than c-MYC in stage 4-NA tumors. Whether this effect is due to the cellular context in which they are expressed and/or due to different functions of the two MYC proteins in neuroblastoma cells is unclear. In favor of a cellular context factor, we observed that promoter constructs from the PTMA gene, which is highly expressed in stage 4s NA and MYCN amplified tumors, showed a strong activation in N-type but not S-type neuroblastoma cell lines despite similar MYCN protein levels (unpublished data). In favor of different functions of the two MYC proteins, our analyses in SH-EPMYCN cells suggest that a large number of MYCN/c-MYC target genes (subgroup I genes) are less responsive to MYCN than to c-MYC. Another unsolved question is which molecular mechanisms induce elevated MYCN activity in stage 4s-NA tumors or elevated c-MYC activity in stage 4-NA tumors. Candidate pathways involved in differential regulation of MYC proteins are the Sonic hedgehog pathway (Shh) for MYCN activation [30] and the Wnt/beta-catenin pathway for c-MYC activation [31,32]. However, we observed that c-MYC mRNA levels are not significantly higher in stage 4-NA than in localized-NA tumors. This suggests that molecular mechanisms that increase c-MYC protein abundance/stability or simply c-MYC activity are involved in MYCN/c-MYC target gene activation in stage 4 tumors.
###end p 38
###begin p 39
###xml 438 443 438 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 484 486 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 592 596 592 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCT4</italic>
###xml 598 601 598 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FBL</italic>
###xml 603 607 603 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2</italic>
###xml 609 612 609 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NCL</italic>
###xml 614 618 614 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NPM1</italic>
###xml 620 624 620 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTMA</italic>
###xml 630 634 630 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
###xml 727 732 727 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1141 1146 1141 1146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 1175 1179 1175 1179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2</italic>
###xml 1384 1389 1384 1389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 1393 1398 1393 1398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 1455 1460 1455 1460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1772 1777 1772 1777 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MDM2 </italic>
###xml 1792 1796 1792 1796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p14 </italic>
###xml 1822 1827 1822 1827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 1921 1923 1921 1923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 2119 2121 2119 2121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 2122 2124 2122 2124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1911 1919 <span type="species:ncbi:9606">patients</span>
Our data are in line with a model where stage 4s-NA tumors exhibit a moderate MYCN function gain compared to localized-NA tumors. Both subtypes usually have favorable outcome. Most localized-NA tumors are cured by surgery alone or even regress spontaneously. Stage 4s-NA tumors frequently regress spontaneously but regression can also be induced by a 'mild' chemotherapy. We found that stage 4s-NA tumors express, on average, the highest MYCN mRNA levels of all non-amplified tumors [14]. From the experimentally defined direct MYCN target genes, only a restricted set of 25 genes, including CCT4, FBL, MDM2, NCL, NPM1, PTMA, and TP53, was overexpressed in stage 4s-NA compared to localized-NA tumors, indicating that elevated MYCN in stage 4s-NA tumors only partially activates its downstream target genes. On the one hand, this suggests that moderate MYCN function gain in stage 4s-NA tumors is involved in the metastatic phenotype. On the other hand, moderate MYCN function gain in this subtype is still compatible with, or might even favor, spontaneous regression. From the list of MYCN target genes overexpressed in stage 4s-NA tumors, TP53 as a pro-apoptotic gene, and MDM2, coding for the direct inhibitor of p53 and mediating pro-tumorigenic activities, are strong candidates to be involved in the unique phenotype of stage 4s-NA tumors. However, it is important to note that TP53 and MDM2 are co-expressed at higher levels also in stage 4-NA and MYCN amplified tumors. Both subtypes initially respond to therapy, but rapidly acquire resistance and frequently show progression/relapse, suggesting that additional conditions activating MDM2 and/or suppressing TP53 functions are acquired. In line with this, alterations disrupting the p14-MDM2-p53 pathway, such as MDM2 amplification, p14 methylation/deletion, and TP53 mutations are found in neuroblastoma cell lines that were established from relapsed patients [33]. In this context, it remains to be shown whether small compounds that selectively inhibit MDM2, such as nutlin-3, and that induce proliferation arrest and apoptosis in neuroblastoma cell lines [34,35] represent a new therapeutic option for high-risk neuroblastomas.
###end p 39
###begin title 40
Conclusions
###end title 40
###begin p 41
###xml 179 183 179 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 446 448 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 449 451 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 452 454 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
High expression of a defined subset of direct MYCN/c-MYC target genes turned out to be a robust marker for poor overall survival independent of the established markers, amplified MYCN, disease stage (stage 4 versus stages 1, 2, 3, and 4s) and age at diagnosis (>/=1.5 years). Recently, several gene expression-based neuroblastoma risk stratification systems have been developed that predict outcome more accurately than established risk markers [24,28,29]. Unfortunately, the classifier gene lists emerging from these studies hardly overlap, which has been ascribed to the different composition of the investigated cohorts and the different high-throughput gene expression platforms used. Our data show that markers of increased MYCN/c-MYC activity are consistently represented in these classifier gene lists, indicating that a gene expression-based classifier that reflects MYCN/c-MYC function should make an attractive tool for neuroblastoma classification and risk prediction.
###end p 41
###begin title 42
Materials and methods
###end title 42
###begin title 43
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 43
###begin p 44
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 159 166 <span type="species:ncbi:9606">patient</span>
###xml 313 320 <span type="species:ncbi:9606">patient</span>
All patients from this study (n = 251) were enrolled in the German Neuroblastoma Trials NB90-NB2004 with informed consent and diagnosed between 1989 and 2004 (patient characteristics are in Additional data files 2 and 12). Tumor samples were collected prior to any cytoreductive treatment. The only criterion for patient selection was availability of sufficient amounts of tumor material. Tumor specimens were checked for at least 60% tumor content.
###end p 44
###begin title 45
Neuroblastoma sample preparation and gene expression analysis
###end title 45
###begin p 46
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 436 441 436 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 627 629 627 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 630 632 630 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 924 926 924 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
Gene expression profiles from the tumors were generated as dye-flipped dual-color replicates using customized 11K oligonucleotide microarrays as previously described [24]. The 11K Agilent microarray was constructed in our laboratory based on extensive neuroblastoma transcriptome information from different whole-genome analyses from primary tumors and neuroblastoma cell lines. These also include comparative transcriptome analysis of MYCN amplified versus not amplified tumors as well as of neuroblastoma cell lines with variable/conditional MYCN/c-MYC expression that allowed the enrichment with MYCN/c-MYC-regulated genes [14,24] (unpublished data). The reference for each tumor RNA was an RNA pool of 100 neuroblastoma tumor samples. Data normalization and quality control is described in Additional data file 2. All raw and normalized microarray data are available at the ArrayExpress database (Accession: E-TABM-38) [36].
###end p 46
###begin title 47
Neuroblastoma cell line experiments and SOM analysis
###end title 47
###begin p 48
###xml 9 14 9 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 9 14 9 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN </italic></sup>
###xml 60 62 60 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 78 83 78 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 228 233 228 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 307 312 307 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 307 312 307 312 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN </italic></sup>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 565 570 565 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 565 570 565 570 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN </italic></sup>
###xml 582 587 582 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 615 620 615 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 615 620 615 620 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN </italic></sup>
###xml 657 662 657 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 709 714 709 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 709 714 709 714 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN </italic></sup>
###xml 953 955 952 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
The SH-EPMYCN cell line, previously also denoted as TET21N [23], expressing a MYCN transgene under the control of a tetracycline-repressible element was used to generate gene expression profiles from different time points after MYCN induction showing variable MYCN and c-MYC levels. RNA isolation from SH-EPMYCN cells was performed as previously described [14]. Gene expression profiles were generated as dye-flipped dual-color replicates using the same customized 11K oligonucleotide microarray platform used for the tumor samples. The reference for RNA from SH-EPMYCN cells after MYCN induction was RNA from SH-EPMYCN cells cultured in parallel that lack MYCN expression. Gene expression profiles from SH-EPMYCN cells with variable MYCN and c-MYC levels were taken for a SOM analysis (Additional data file 2). Protein expression was assessed by immunoblotting using 50 mug of total cell lysates from the cell line experiments as previously described [37]. Blots were probed with antibodies directed against MYCN (SantaCruz, sc-53993, Santa Cruz, CA, USA) and c-MYC (SantaCruz, sc-764, Santa Cruz, CA, USA).
###end p 48
###begin title 49
ChIP, ChIP-chip and protein analysis
###end title 49
###begin p 50
###xml 69 71 69 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 72 74 72 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 147 149 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 150 152 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 308 316 306 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IMR5/75 </italic>
###xml 320 325 318 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SH-EP</italic>
###xml 325 330 323 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 325 330 323 328 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN </italic></sup>
###xml 488 493 486 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SH-EP</italic>
###xml 493 497 491 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 493 497 491 495 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN</italic></sup>
###xml 499 504 497 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SH-EP</italic>
###xml 506 511 504 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kelly</italic>
###xml 513 520 511 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IMR5/75</italic>
###xml 522 530 520 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SJNB-12 </italic>
###xml 534 539 532 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SY5Y </italic>
###xml 722 724 720 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 957 967 955 965 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in silico </italic>
###xml 165 170 <span type="species:ncbi:10090">mouse</span>
###xml 629 634 <span type="species:ncbi:9606">Human</span>
Chromatin immunoprecipitation was performed as described previously [38,39] using 10 mug of MYCN (SantaCruz, sc-53993), c-MYC (SantaCruz, sc-764) [40,41] and normal mouse IgG (SantaCruz, sc-2025) antibodies and Dynabeads ProteinG (Invitrogen, Carlsbad, CA, USA). Eluted and purified MYCN-ChIP-DNA (1 mul) of IMR5/75 and SH-EPMYCN was used as a template in PCR reactions running for 35 cycles. The primer sequences are given in Additional data file 8. In addition, ChIP-DNA templates from SH-EPMYCN, SH-EP, Kelly, IMR5/75, SJNB-12 and SY5Y cells using MYCN and c-MYC antibodies were amplified for DNA microarray analysis (Agilent Human Promoter ChIP-chip Set 244K) using the WGA (Sigma-Aldrich, St. Louis, MO, USA) method [42]. DNA labeling, array hybridization and measurement were performed according to Agilent mammalian ChIP-chip protocols. For the visualization of ChIP-chip results, the cureos package v0.2 for R was used (available upon request). The in silico promoter analysis for the identification of putative MYC binding sites (canonical and non-canonical E-boxes) is described in Additional data file 2.
###end p 50
###begin title 51
Differential gene expression and survival analysis
###end title 51
###begin p 52
###xml 32 36 32 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 136 141 136 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 322 323 322 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 377 382 377 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 468 470 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 565 579 565 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN in vitro </italic>
###xml 679 681 679 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 845 850 845 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1040 1041 1038 1039 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1101 1103 1099 1101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 527 535 <span type="species:ncbi:9606">patients</span>
Differential gene expression of MYCN/c-MYC and their target genes in neuroblastoma tumors was evaluated for stage 4s-NA, stage 4-NA and MYCN amplified using localized-NA tumors (stages 1, 2, 3) as reference using Goeman's Global test and the Wilcoxon rank sum test. A result was judged as 'statistically significant' at a p-value of 0.05 or smaller. Differential expression of MYCN was evaluated in two partially overlapping cohorts, one measured by quantitative PCR [14] and the other by oligo microarray (the overlap was 101 patients). To test the association of MYCN in vitro clusters with overall survival (death due to neuroblastoma disease), Goeman's Global test was used [27]. To evaluate the influence of gene expression on outcome independent of established markers, the Global test was adjusted for the following co-variables: genomic MYCN status, stage of the disease (stage 4 versus stages 1, 2, 3, and 4s), and age at diagnosis (>/=1.5 years versus <1.5 years). Because of multiple testing of probably dependent gene clusters, p-values were adjusted according to Benjamini and Yekutieli [43] to control the false discovery rate of 5%.
###end p 52
###begin title 53
Abbreviations
###end title 53
###begin p 54
ChIP, PCR-based chromatin immunoprecipitation; ChIP-chip, array-based chromatin immunoprecipitation; NA, non-amplified; SOM, self-organizing map.
###end p 54
###begin title 55
Authors' contributions
###end title 55
###begin p 56
###xml 298 308 298 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in silico </italic>
FW designed and coordinated the study. FW and DM interpreted results and drafted the manuscript. AO, MF, AB, BB and FW carried out array-based expression profiling and data analyses of neuroblastoma tumor samples and cell lines. BH was responsible for clinical data management. TB and RK performed in silico promoter analyses. JV and FP contributed samples and performed literature searches of MYCN/c-MYC target genes. DM performed chromatin immunoprecipitation experiments. DM, TB and FW analyzed ChIP-chip data. AB, BH and FW carried out global test and survival analyses. FW, DM, KOH, JV, FP and MS contributed to the manuscript. All authors read and approved the final manuscript.
###end p 56
###begin title 57
Additional data files
###end title 57
###begin p 58
###xml 66 67 66 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 193 198 193 198 <sup xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </sup>
###xml 226 227 226 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 317 318 317 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">3</xref>
###xml 323 324 323 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S4">4</xref>
###xml 457 458 457 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S5">5</xref>
###xml 460 461 460 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S6">6</xref>
###xml 466 467 466 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S7">7</xref>
###xml 556 561 556 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 647 648 647 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S8">8</xref>
###xml 742 743 742 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S9">9</xref>
###xml 745 747 745 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S10">10</xref>
###xml 752 754 752 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S11">11</xref>
###xml 891 893 891 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S12">12</xref>
###xml 915 922 <span type="species:ncbi:9606">patient</span>
The following additional data are available. Additional data file 1 is a figure showing a Cluster map of genetic programs regulated by conditional expression of c-MYC and MYCN proteins in SH-EPMYCN cells. Additional data file 2 is a document describing in more detail the methods and materials. Additional data files 3 and 4 are sets of figures showing ChIP-chip results of MYCN/c-MYC target genes in the Kelly and SJ-NB12 cell lines. Additional data files 5, 6 and 7 are tables listing MYCN/c-MYC target genes overexpressed in stage 4s-NA, stage 4-NA and MYCN amplified tumors, respectively, compared to localized-NA tumors. Additional data file 8 is a table of genes and primers selected to confirm ChIP-chip results. Additional data files 9, 10 and 11 are figures showing the association of MYCN/c-MYC induced genes with neuroblastoma subtypes using the Global test. Additional data file 12 is a table providing patient data.
###end p 58
###begin title 59
Supplementary Material
###end title 59
###begin title 60
Additional data file 1
###end title 60
###begin p 61
###xml 103 108 103 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </sup>
Cluster map of genetic programs regulated by conditional expression of c-MYC and MYCN proteins in SH-EPMYCN cells.
###end p 61
###begin p 62
Click here for file
###end p 62
###begin title 63
Additional data file 2
###end title 63
###begin p 64
Detailed methods and materials.
###end p 64
###begin p 65
Click here for file
###end p 65
###begin title 66
Additional data file 3
###end title 66
###begin p 67
ChIP-chip results of MYCN/c-MYC target genes in the Kelly cell line.
###end p 67
###begin p 68
Click here for file
###end p 68
###begin title 69
Additional data file 4
###end title 69
###begin p 70
ChIP-chip results of MYCN/c-MYC target genes in the SJ-NB12 cell line.
###end p 70
###begin p 71
Click here for file
###end p 71
###begin title 72
Additional data file 5
###end title 72
###begin p 73
MYCN/c-MYC target genes, which grouped in class 1 and 2.
###end p 73
###begin p 74
Click here for file
###end p 74
###begin title 75
Additional data file 6
###end title 75
###begin p 76
MYCN/c-MYC target genes, which grouped in class 4.
###end p 76
###begin p 77
Click here for file
###end p 77
###begin title 78
Additional data file 7
###end title 78
###begin p 79
MYCN/c-MYC target genes, which grouped in class 3.
###end p 79
###begin p 80
Click here for file
###end p 80
###begin title 81
Additional data file 8
###end title 81
###begin p 82
Genes and primers selected to confirm ChIP-chip results.
###end p 82
###begin p 83
Click here for file
###end p 83
###begin title 84
Additional data file 9
###end title 84
###begin p 85
Association of MYCN/c-MYC induced genes with stage 4s-NA neuroblastomas using the Global test.
###end p 85
###begin p 86
Click here for file
###end p 86
###begin title 87
Additional data file 10
###end title 87
###begin p 88
Association of MYCN/c-MYC induced genes with stage 4-NA neuroblastomas using the Global test.
###end p 88
###begin p 89
Click here for file
###end p 89
###begin title 90
Additional data file 11
###end title 90
###begin p 91
###xml 45 50 45 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
Association of MYCN/c-MYC induced genes with MYCN amplified neuroblastomas using the Global test.
###end p 91
###begin p 92
Click here for file
###end p 92
###begin title 93
Additional data file 12
###end title 93
###begin p 94
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient data.
###end p 94
###begin p 95
Click here for file
###end p 95
###begin title 96
Acknowledgements
###end title 96
###begin p 97
We thank Steffen Bannert and Yvonne Kahlert for technical assistance. We thank the German Neuroblastoma Tumor Bank for providing tumor samples, the German Neuroblastoma Study Group (study chair Frank Berthold) for providing clinical data and the reference laboratories for providing molecular data. This work was supported by program project grants from the Krebshilfe, BMBF (NGFN2 and Kompetenznetz Pediatric Oncology/Hematology) and the EU. The platform iCHIP (Integration Center of HIgh throughPut experiments) has been used for the annotation of this study. Jo Vandesompele is a postdoctoral researcher of the Research Foundation - Flanders (FWO-Vlaanderen). Filip Pattyn is supported by a grant of the Ghent University Special Research Fund (BOF).
###end p 97
###begin article-title 98
Neuroblastoma: biology and molecular and chromosomal pathology.
###end article-title 98
###begin article-title 99
Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma.
###end article-title 99
###begin article-title 100
Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.
###end article-title 100
###begin article-title 101
###xml 52 67 <span type="species:ncbi:10090">transgenic mice</span>
Targeted expression of MYCN causes neuroblastoma in transgenic mice.
###end article-title 101
###begin article-title 102
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human N-myc gene contributes to neoplastic transformation of mammalian cells in culture.
###end article-title 102
###begin article-title 103
Transcriptional regulation and transformation by Myc proteins.
###end article-title 103
###begin article-title 104
Mechanisms of transcriptional repression by Myc.
###end article-title 104
###begin article-title 105
The ever expanding role for c-Myc in promoting genomic instability.
###end article-title 105
###begin article-title 106
MycN sensitizes neuroblastoma cells for drug-induced apoptosis.
###end article-title 106
###begin article-title 107
Why does stage 4s neuroblastoma regress spontaneously?
###end article-title 107
###begin article-title 108
###xml 36 43 <span type="species:ncbi:9606">infants</span>
Mass screening for neuroblastoma in infants in Japan. Interim report of a mass screening study group.
###end article-title 108
###begin article-title 109
A population-based study of the usefulness of screening for neuroblastoma.
###end article-title 109
###begin article-title 110
###xml 0 8 <span type="species:ncbi:9606">Children</span>
Children may not benefit from neuroblastoma screening at 1 year of age. Updated results of the population based controlled trial in Germany.
###end article-title 110
###begin article-title 111
High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN status.
###end article-title 111
###begin article-title 112
MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN.
###end article-title 112
###begin article-title 113
The MYCN enigma: significance of MYCN expression in neuroblastoma.
###end article-title 113
###begin article-title 114
###xml 44 49 <span type="species:ncbi:9606">human</span>
MycN and IFNgamma cooperate in apoptosis of human neuroblastoma cells.
###end article-title 114
###begin article-title 115
Neuroblastoma cells with overexpressed MYCN retain their capacity to undergo neuronal differentiation.
###end article-title 115
###begin article-title 116
###xml 82 87 <span type="species:ncbi:9606">human</span>
Expression of neurotransmitter receptors and myc protooncogenes in subclones of a human neuroblastoma cell line.
###end article-title 116
###begin article-title 117
###xml 49 54 <span type="species:ncbi:9606">human</span>
Suppression of MYC by high expression of NMYC in human neuroblastoma cells.
###end article-title 117
###begin article-title 118
The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.
###end article-title 118
###begin article-title 119
N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis.
###end article-title 119
###begin article-title 120
###xml 35 40 <span type="species:ncbi:9606">human</span>
Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells.
###end article-title 120
###begin article-title 121
###xml 92 100 <span type="species:ncbi:9606">patients</span>
Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification.
###end article-title 121
###begin article-title 122
An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets.
###end article-title 122
###begin article-title 123
TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes.
###end article-title 123
###begin article-title 124
Testing association of a pathway with survival using gene expression data.
###end article-title 124
###begin article-title 125
Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling.
###end article-title 125
###begin article-title 126
Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas.
###end article-title 126
###begin article-title 127
N-myc is an essential downstream effector of Shh signaling during both normal and neoplastic cerebellar growth.
###end article-title 127
###begin article-title 128
Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification.
###end article-title 128
###begin article-title 129
The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells.
###end article-title 129
###begin article-title 130
Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse.
###end article-title 130
###begin article-title 131
Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma.
###end article-title 131
###begin article-title 132
MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death.
###end article-title 132
###begin article-title 133
ArrayExpress-a public repository for microarray gene expression data at the EBI.
###end article-title 133
###begin article-title 134
###xml 31 36 <span type="species:ncbi:9606">human</span>
Ataxin-2 promotes apoptosis of human neuroblastoma cells.
###end article-title 134
###begin article-title 135
E2F proteins regulate MYCN expression in neuroblastomas.
###end article-title 135
###begin article-title 136
Chromatin immunoprecipitation and microarray-based analysis of protein location.
###end article-title 136
###begin article-title 137
Myc influences global chromatin structure.
###end article-title 137
###begin article-title 138
###xml 36 41 <span type="species:ncbi:9606">human</span>
Myc-binding-site recognition in the human genome is determined by chromatin context.
###end article-title 138
###begin article-title 139
Comparison of sample preparation methods for ChIP-chip assays.
###end article-title 139
###begin article-title 140
The control of the false discovery rate in multiple testing under dependency.
###end article-title 140
###begin article-title 141
Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.
###end article-title 141
###begin article-title 142
Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines.
###end article-title 142
###begin article-title 143
CRAN
###end article-title 143
###begin article-title 144
Bioconductor
###end article-title 144
###begin article-title 145
arrayMagic: two-colour cDNA microarray quality control and preprocessing.
###end article-title 145
###begin article-title 146
Variance stabilization applied to microarray data calibration and to the quantification of differential expression.
###end article-title 146
###begin article-title 147
Ensembl 2007.
###end article-title 147
###begin article-title 148
MYCNot
###end article-title 148
###begin article-title 149
SOM Toolbox
###end article-title 149

